Ficlatuzumab + Erlotinib + placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Nov 1, 2014 → Jan 1, 2017
NCT ID
NCT02318368About Ficlatuzumab + Erlotinib + placebo
Ficlatuzumab + Erlotinib + placebo is a phase 2 stage product being developed by Biodesix for Non-small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02318368. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02318368 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-small Cell Lung Cancer